# US 2010/0136042 A1 · Globo h and related anti-cancer vaccines with novel glycolipid adjuvants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136042 A1
- Document ID: US20100136042A1
- Status: Published application
- Kind: A1
- Application number: 12/537,129
- Filed: 2009-08-06
- Published: 2010-06-03
- Earliest claimed: 2008-06-16
- Assignees: Academia Sinica
- Inventors: Chi-Huey Wong; Chung-Yi Wu; Alice Yu; John Yu
- Web page: https://patentgrep.com/patent/US20100136042A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 39/001173: {Globo-H}
- A61K 39/00118: {from embryonic or fetal origin}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- A61K 2039/627: {characterised by the linker}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions comprising: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CD1d on a dendritic cell, such as an α-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions comprising the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM197.

## Claims

### Claim 1

An immunogenic composition comprising:
(a) a glycan consisting essentially of Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein through a linker; and
(b) an adjuvant comprising a glycolipid capable of binding a CD1d molecule on a dendritic cell,
wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the carrier protein is diphtheria toxin cross-reacting material 197 (DT-CRM197).

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein the adjuvant is a synthetic analog of α-galactosyl-ceramide (α-GalCer).

### Claim 4 (depends on 3)

The immunogenic composition of claim 3, wherein the adjuvant is C34, wherein C34 comprises the structure:

### Claim 5 (depends on 1)

The immunogenic composition of claim 1, wherein the linker is a p-nitrophenyl linker.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1, wherein the linker is p-nitrophenyl, the carrier protein is diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant is C34.

### Claim 7 (depends on 1)

The immunogenic composition of claim 1, wherein the immune response is preferably oriented towards the production of IgG isotype antibodies.

### Claim 8 (depends on 7)

The immunogenic composition of claim 7, wherein the carrier protein is diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant is C34.

### Claim 9 (depends on 1)

The immunogenic composition of claim 1 comprising at least one adjuvant able to induce a humoral and cellular immune response.

### Claim 10 (depends on 1)

The immunogenic composition of claim 1, wherein the antibodies generated by the immune response neutralize antigens expressed on cancer cells or cancer stem cells.

### Claim 11 (depends on 10)

The immunogenic composition of claim 10, wherein the antibodies generated by the immune response neutralize at least one of the antigens Gb4, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4).

### Claim 12 (depends on 11)

The immunogenic composition of claim 11, wherein the antibodies that neutralize at least one of the antigens Gb4, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4) comprise a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies.

### Claim 13 (depends on 11)

The immunogenic composition of claim 11, wherein the carrier protein is diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant is C34.

### Claim 14 (depends on 1)

The immunogenic composition of claim 1, further comprising a cancer vaccine composition able to induce anti-cancer immune responses in a subject.

### Claim 15 (depends on 14)

The cancer vaccine of claim 14, wherein the cancer vaccine is suitable for treating a cancer selected from the group consisting of: breast cancer, lung cancer, liver cancer, buccal cancer, stomach cancer, colon cancer, nasopharyngeal cancer, dermal cancer, renal cancer, brain tumor, prostate cancer, ovarian cancer, cervical cancer, intestinal cancer, and bladder cancer.

### Claim 16 (depends on 15)

The cancer vaccine of claim 15, wherein the cancer tissue expresses a Globo H antigen on the surface of the cell.

### Claim 17 (depends on 15)

The cancer vaccine of claim 15, wherein the Globo H antigen is expressed on an epithelial cell of a breast tumor.

### Claim 18 (depends on 14)

The cancer vaccine of claim 14, wherein the antibodies generated by the immune response neutralize at least one of the antigens Globo H, Gb4, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4).

### Claim 19 (depends on 14)

The cancer vaccine of claim 14, wherein at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4) is expressed on a breast cancer stem cell.

### Claim 20

A method of treatment comprising inhibition of tumor growth, the method comprising:
(a) administering to a subject in need thereof, an immunogenic composition comprising: a glycan consisting essentially of Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein through a linker, and an adjuvant comprising a glycolipid capable of binding a CD1d molecule on a dendritic cell; and
(b) inducing an immune response that induces a higher relative amount of IgG isotype antibodies as compared to IgM isotype antibodies.

### Claim 21 (depends on 20)

The method of claim 20, wherein in the immunogenic composition the linker is p-nitrophenol, the carrier protein is diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant is a synthetic analog of α-galactosyl-ceramide (α-GalCer).

### Claim 22 (depends on 21)

The method of claim 21, wherein the adjuvant is C34.

### Claim 23 (depends on 20)

The method of claim 20, wherein the immunogenic composition further comprises a cancer vaccine, and further wherein one or more treatments with an effective amount of the cancer vaccine inhibits tumor growth.

### Claim 24 (depends on 23)

The method of claim 23, wherein administration of the cancer vaccine reduces the size of a tumor.

### Claim 25 (depends on 23)

The method of claim 23, wherein the cancer is selected from the group consisting of: breast cancer, lung cancer, liver cancer, buccal cancer, stomach cancer, colon cancer, nasopharyngeal cancer, dermal cancer, renal cancer, brain tumor, prostate cancer, ovarian cancer, cervical cancer, intestinal cancer, and bladder cancer.

### Claim 26 (depends on 21)

The method of claim 21, wherein the immune response is preferably oriented towards the production of IgG isotype antibodies.

### Claim 27 (depends on 20)

The method of claim 20, wherein the antibodies generated by the immune response neutralize at least one of the antigens Globo H, Gb4, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4).

### Claim 28 (depends on 27)

The method of claim 27, wherein at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4) is expressed on a breast cancer stem cell.

### Claim 29 (depends on 27)

The method of claim 27, wherein the Globo H antigens is expressed on an epithelial cell of a breast tumor.

### Claim 30 (depends on 27)

The method of claim 27, wherein the antibodies that neutralize at least one of the antigens Gb4, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4) comprise a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies.

### Claim 31

A cancer vaccine comprising:
(a) an immunogenic composition comprising: a glycan consisting essentially of Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein through a linker, and an adjuvant comprising a glycolipid capable of binding a CD1d molecule on a dendritic cell, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies; and
(b) a pharmaceutically acceptable excipient.

### Claim 32 (depends on 31)

The cancer vaccine according to claim 31, wherein in the immunogenic composition the linker is p-nitrophenol, the carrier protein is diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant is a synthetic analog of α-galactosyl-ceramide (α-GalCer).

### Claim 33 (depends on 32)

The cancer vaccine according to claim 32, wherein the adjuvant is C34.

### Claim 34 (depends on 32)

The cancer vaccine of claim 32, wherein the cancer is breast cancer, and
wherein a Globo H antigen is expressed on an epithelial cell of a breast tumor.

### Claim 35 (depends on 32)

The cancer vaccine of claim 32, wherein the antibodies generated by the immune response neutralize at least one of the antigens Globo H, Gb4, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4).

### Claim 36 (depends on 32)

The cancer vaccine of claim 32, wherein the cancer is breast cancer, and
wherein at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4) is expressed on a breast cancer stem cell.

### Claim 37

An immunogenic composition comprising:
(a) a glycan consisting essentially of a Globo H-related glycan or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein through a linker; and
(b) an adjuvant comprising a glycolipid capable of binding a CD1d molecule on a dendritic cell,
wherein the Globo H-related glycan is selected from the group consisting of SSEA-3 and SSEA-4, and wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies.

### Claim 38 (depends on 37)

The immunogenic composition of claim 37, wherein the carrier protein is diphtheria toxin cross-reacting material 197 (DT-CRM197).

### Claim 39 (depends on 37)

The immunogenic composition of claim 37, wherein the adjuvant is a synthetic analog of α-galactosyl-ceramide (α-GalCer).

### Claim 40 (depends on 39)

The immunogenic composition of claim 39, wherein the adjuvant is C34, wherein C34 comprises the structure:

### Claim 41 (depends on 37)

The immunogenic composition of claim 37, wherein the linker is a p-nitrophenyl linker.

### Claim 42 (depends on 37)

The immunogenic composition of claim 37, wherein the linker is p-nitrophenyl, the carrier protein is diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant is C34.

### Claim 43

A therapeutic against breast cancer stem cells, the therapeutic comprising:
Globo H conjugated through a p-nitrophenyl linker with a diphtheria toxin cross-reacting material 197 (DT-CRM197) carrier protein; and
an adjuvant comprising a glycolipid capable of binding a CD1d molecule on a dendritic cell.

### Claim 44 (depends on 43)

The therapeutic of claim 43, wherein the adjuvant is C34.

### Claim 45 (depends on 43)

The therapeutic of claim 43, wherein administration of the therapeutic to a subject induces production of antibodies that recognize an antigen expressed on a breast cancer stem cell (BCSC)

### Claim 46 (depends on 44)

The therapeutic of claim 44, wherein the at least one antigen is selected from the group consisting of Globo H, SSEA-3 and SSEA-4.

### Claim 47

A therapeutic against breast cancer stem cells, the therapeutic comprising:
SSEA-3 conjugated through a p-nitrophenyl linker with a diphtheria toxin cross-reacting material 197 (DT-CRM197) carrier protein; and
an adjuvant comprising a glycolipid C34 capable of binding a CD1d molecule on a dendritic cell.

### Claim 48 (depends on 47)

The therapeutic of claim 47, wherein administration of the therapeutic to a subject induces production of antibodies that recognize an antigen expressed on a breast cancer stem cell (BCSC)

### Claim 49 (depends on 48)

The therapeutic of claim 48, wherein the at least one antigen is selected from the group consisting of Globo H, SSEA-3 and SSEA-4.

### Claim 50

A therapeutic against breast cancer stem cells, the therapeutic comprising:
SSEA-4 conjugated through a p-nitrophenyl linker with a diphtheria toxin cross-reacting material 197 (DT-CRM197) carrier protein.

### Claim 51 (depends on 50)

The therapeutic of claim 50, further comprising an adjuvant comprising a glycolipid capable of binding a CD1d molecule on a dendritic cell.

### Claim 52 (depends on 51)

The therapeutic of claim 51, wherein the adjuvant is C34.

### Claim 53 (depends on 50)

The therapeutic of claim 50, wherein administration of the therapeutic to a subject induces production of antibodies that recognize SSEA-4, or truncated structures thereof that are expressed on a breast cancer stem cell (BCSC).

### Claim 54 (depends on 43)

A method for treating breast cancer, the method comprising administering to a subject in need thereof, a therapeutic composition according to claim 43.

### Claim 55 (depends on 47)

A method for treating breast cancer, the method comprising administering to a subject in need thereof, a therapeutic composition according to claim 47.

### Claim 56 (depends on 50)

A method for treating breast cancer, the method comprising administering to a subject in need thereof, a therapeutic composition according to claim 50.
